Table 3. Summary of costs and benefits, 2017–2030.
| Scenarios compared | Total cost (USD) | Estimated clinical
cases averted |
Deaths averted | Economic benefits
(USD) |
Incremental
cost (USD) |
ROI |
|---|---|---|---|---|---|---|
| Business as usual
vs. elimination (with resistance assumption) |
29.024 billion
(range: 23.64–36.23) |
123.14 million
(estimated) 4 16.54 million (reported) 5 |
386,167
(estimated) 193,084 (reported) |
87.73 billion
(range: 26.3–347.14) |
14.05 billion | 6:1 |
| Business as usual vs.
elimination (baseline) |
28.953 billion
(range: 23.38–35.72) |
92.23 million
(estimated clinical) 11.68 million (reported) |
264,322
(estimated clinical) 132,161 (reported) |
72.90 billion | 13.79 billion | 5:1 |
| Reverse vs. elimination
(with resistance assumption) |
NA | 845.73 million | 3.487 million | N/A | 6.693 billion | N/A |